Related Experiment Video
Updated: Nov 16, 2025
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Selective Inhibition of the Hsp90α Isoform
Sanket J Mishra1, Anuj Khandelwal1, Monimoy Banerjee1
1Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN, 46556, USA.
Abstract:
The 90 kDa heat shock protein (Hsp90) is a molecular chaperone that processes nascent polypeptides into their biologically active conformations. Many of these proteins contribute to the progression of cancer, and consequently, inhibition of the Hsp90 protein folding machinery represents an innovative approach toward cancer chemotherapy. However, clinical trials with Hsp90 N-terminal inhibitors have encountered deleterious side effects and toxicities, which appear to result from the pan-inhibition of all four Hsp90 isoforms. Therefore, the development of isoform-selective Hsp90 inhibitors is sought to delineate the pathological role played by each isoform. Herein, we describe a structure-based approach that was used to design the first Hsp90α-selective inhibitors, which exhibit >50-fold selectivity versus other Hsp90 isoforms.
Insights
Researchers developed novel Hsp90α-selective inhibitors to overcome side effects of current cancer drugs. These compounds target a specific heat shock protein (Hsp90) isoform, offering a more precise approach to cancer chemotherapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Heat shock protein 90 (Hsp90) is crucial for protein folding and cancer progression.
- Current Hsp90 inhibitors cause side effects due to broad isoform inhibition.
- Targeting specific Hsp90 isoforms is needed for safer cancer therapy.
Purpose of the Study:
- To design the first Hsp90α-selective inhibitors.
- To develop targeted cancer chemotherapy with reduced toxicity.
Main Methods:
- Structure-based drug design.
- Synthesis and testing of novel Hsp90 inhibitors.
- Isoform selectivity assays.
Main Results:
- Successfully designed the first Hsp90α-selective inhibitors.
- Achieved >50-fold selectivity for Hsp90α over other isoforms.
- Demonstrated a promising approach for targeted cancer treatment.
Conclusions:
- Hsp90α-selective inhibitors offer a potential new strategy for cancer treatment.
- This approach may reduce the toxicities associated with current Hsp90 inhibitors.
- Further research into isoform-specific Hsp90 inhibition is warranted.
Related Concept Videos
03:00Molecular Chaperones and Protein Folding
The...
01:20The JAK-STAT Signaling Pathway
01:12GPCR Desensitization
00:46Feedback Inhibition